ClinVar Miner

Submissions for variant NM_000053.4(ATP7B):c.2575+1G>C (rs766149114)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 2
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Counsyl RCV000169063 SCV000220227 likely pathogenic Wilson disease 2014-04-09 criteria provided, single submitter literature only
Integrated Genetics/Laboratory Corporation of America RCV000169063 SCV000694425 likely pathogenic Wilson disease 2017-08-21 criteria provided, single submitter clinical testing Variant summary: The ATP7B c.2575+1G>C variant involves the alteration of a conserved intronic nucleotide. One in silico tool predicts a damaging outcome for this variant. 5/5 splice prediction tools predict a significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. This variant was found in the large control database ExAC in 1/120766 control chromosomes at a frequency of 0.0000083, which does not exceed the estimated maximal expected allele frequency of a pathogenic ATP7B variant (0.0054006). This variant was reported in multiple Wilson Disease patients, including in two of British origin in compound heterozygosity with ATP7B c.331C>T/p.Gln111Term (not in our internal database, DM in HGMD). In addition, multiple clinical diagnostic laboratories/reputable databases classified this variant as likely pathogenic. Taken together, this variant is classified as likely pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.